T.Man Pharmaceutical PCL (BKK:TMAN)

Thailand · Delayed Price · Currency is THB

10.30

+0.20 (1.98%)

Last updated: Sep 3, 2026, 2:30 PM ICT

-9.65% (1Y)

Market Cap	4.08B -10.5%
Revenue (ttm)	2.62B +16.4%
Net Income	506.59M +14.9%
EPS	1.27 +9.2%
Shares Out	400.00M
PE Ratio	8.05
Forward PE	7.89
Dividend	0.56 (5.49%)
Ex-Dividend Date	Aug 26, 2026

Volume	127,664
Open	10.30
Previous Close	10.10
Day's Range	10.20 - 10.40
52-Week Range	9.95 - 13.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 18, 2026

About T.Man Pharmaceutical PCL

T.Man Pharmaceutical Public Company Limited manufactures and sells pharmaceuticals and health care products in Thailand. The company operates through three segments: Manufactured Products Under Own Brand, Manufactured Products Under Third Parties’ Brand, and Trading Products. It offers antibacterial, central nervous system, corticosteroid, chronic diseases, gastrointestinal, respiratory, and musculoskeletal drugs, as well as medical devices, vaginal suppositories, dermatological, mouth, and throat products. The company also provides herbal and ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1991

Employees 944

Stock Exchange Stock Exchange of Thailand

Ticker Symbol TMAN

Full Company Profile

Financial Performance

In 2025, T.Man Pharmaceutical PCL's revenue was 2.53 billion, an increase of 13.48% compared to the previous year's 2.23 billion. Earnings were 523.07 million, an increase of 16.06%.

Financial Statements